Last reviewed · How we verify

liposomal bupivacaine local infiltration

Second Affiliated Hospital, School of Medicine, Zhejiang University · FDA-approved active Small molecule

Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses when infiltrated into tissue.

Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses when infiltrated into tissue. Used for Local infiltration anesthesia for surgical procedures, Postoperative pain management.

At a glance

Generic nameliposomal bupivacaine local infiltration
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine, an amide-type local anesthetic, works by reversibly inhibiting sodium influx through voltage-gated sodium channels in nerve fibers, thereby preventing depolarization and action potential propagation. The liposomal formulation extends the duration of action and reduces systemic toxicity by providing sustained local release of the active agent at the infiltration site.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: